Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Sep 21;2(2):79-81.
doi: 10.1016/j.lrr.2013.08.001. eCollection 2013.

Differential cytogenetic profile in advanced chronic myeloid leukemia with sequential lymphoblastic and myeloblastic blast crisis

C Calderón-Cabrera  1 , I Montero  1 , R M Morales  1 , J Sánchez  2 , E Carrillo  1 , T Caballero-Velázquez  1 , C Prats  1 , R Bernal  1 , J M De Blas  1 , J A Pérez-Simón  1
Affiliations

Differential cytogenetic profile in advanced chronic myeloid leukemia with sequential lymphoblastic and myeloblastic blast crisis

C Calderón-Cabrera et al. Leuk Res Rep. .

Abstract

Frequency of additional chromosomal abnormalities in chronic myeloid leukemia (CML) is estimated to be 7% in chronic phase and increases to 40-70% in advanced disease. Progression of CML from chronic phase to accelerated phase or blast crisis is often associated with secondary chromosomal aberrations. We report an exceptional case of CML as debut in lymphoblastic blast crisis and a subsequent progression in myeloblastic blast crisis with rare cytogenetic abnormalities.

Keywords: Blast crisis; Chronic myeloid leukemia; Cytogenetic abnormalities.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
(A) At diagnosis. Interphase FISH, Vysis dual-fusion probe set. Green: BCR; red: ABL; yellow: fused BCR and ABL signals corresponding to der(9) and der(22) translocation products. (B) At diagnosis. Interfase FISH, Vysis dual color probe set. Green: chromosome 7 centromere; red: locus 7q31. Interphase cells showing one centromere and one 7q31 signal indicating monosomy 7. (C) After treatment: rearrengement BCR/ABL (92%). (D) After treatment: monosomy 7=0%. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
Fig. 2
Fig. 2
(A) Karyotype at diagnosis (lymphoblastic blast crisis): 45,XX,-7,t(9;22)(q34;q11.2)[20]. (B) Karyotype at relapse (myeloblastic blast crisis): 46,XX,t(1;6)(q22;q21),del(4)(p14),t(9;22)(q34;q11.2),der(11)add(11)(p14)add(11)(q23),add(17)(q12~21)[20].
See this image and copyright information in PMC

References

    1. Cortes J.E., Talpaz M., Giles F., O'Brien S., Rios M.B., Shan J. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood. 2003;101:3794–3800. - PubMed
    1. Johansson B., Fioretos T., Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematologica. 2002;107:76–94. - PubMed
    1. Mitelman F, Johansson B, Mertens F. Mitelman Database of chromosome aberrations in cáncer. 2009. 〈http://cgap.nci.nih.gov/Chromosomes/Mitelman〉.
    1. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C. International STI571 CML study group: hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. New England Journal of Medicine. 2002;346:645–652. - PubMed
    1. Strout M.P., Schatz D.G. Imatinib resistance and progression of CML to blast crisis: somatic hypermutation aiding the way. Cancer Cell. 2009;16:174–176. - PubMed

LinkOut - more resources